BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 11717537)

  • 1. Diagnosing primary and metastatic renal cell carcinoma: the use of the monoclonal antibody 'Renal Cell Carcinoma Marker'.
    McGregor DK; Khurana KK; Cao C; Tsao CC; Ayala G; Krishnan B; Ro JY; Lechago J; Truong LD
    Am J Surg Pathol; 2001 Dec; 25(12):1485-92. PubMed ID: 11717537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of renal cell carcinoma antigen (RCC) in renal epithelial and nonrenal tumors: diagnostic Implications.
    Bakshi N; Kunju LP; Giordano T; Shah RB
    Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):310-5. PubMed ID: 17721277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human kidney injury molecule-1 (hKIM-1): a useful immunohistochemical marker for diagnosing renal cell carcinoma and ovarian clear cell carcinoma.
    Lin F; Zhang PL; Yang XJ; Shi J; Blasick T; Han WK; Wang HL; Shen SS; Teh BT; Bonventre JV
    Am J Surg Pathol; 2007 Mar; 31(3):371-81. PubMed ID: 17325478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAX-2 is a helpful marker for diagnosing metastatic renal cell carcinoma: comparison with the renal cell carcinoma marker antigen and kidney-specific cadherin.
    Ozcan A; Zhai Q; Javed R; Shen SS; Coffey D; Krishnan B; Truong LD
    Arch Pathol Lab Med; 2010 Aug; 134(8):1121-9. PubMed ID: 20670131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: an immunohistochemical study with comparison to renal cell carcinoma marker.
    Gokden N; Gokden M; Phan DC; McKenney JK
    Am J Surg Pathol; 2008 Oct; 32(10):1462-7. PubMed ID: 18685487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases.
    Pan CC; Chen PC; Ho DM
    Histopathology; 2004 Nov; 45(5):452-9. PubMed ID: 15500648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms.
    Avery AK; Beckstead J; Renshaw AA; Corless CL
    Am J Surg Pathol; 2000 Feb; 24(2):203-10. PubMed ID: 10680888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAX2 and PAX8 expression in primary and metastatic renal tumors: a comprehensive comparison.
    Ozcan A; de la Roza G; Ro JY; Shen SS; Truong LD
    Arch Pathol Lab Med; 2012 Dec; 136(12):1541-51. PubMed ID: 23194047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney.
    Liao SY; Aurelio ON; Jan K; Zavada J; Stanbridge EJ
    Cancer Res; 1997 Jul; 57(14):2827-31. PubMed ID: 9230182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic utility of renal cell carcinoma marker in cytopathology.
    Gokden N; Mukunyadzi P; James JD; Gokden M
    Appl Immunohistochem Mol Morphol; 2003 Jun; 11(2):116-9. PubMed ID: 12777993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical detection of P504S in primary and metastatic renal cell carcinomas.
    Lin F; Brown RE; Shen T; Yang XJ; Schuerch C
    Appl Immunohistochem Mol Morphol; 2004 Jun; 12(2):153-9. PubMed ID: 15354742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of antiphosphorylated H2AX antibody (gamma-H2AX) in diagnosing metastatic renal cell carcinoma.
    Wasco MJ; Pu RT
    Appl Immunohistochem Mol Morphol; 2008 Jul; 16(4):349-56. PubMed ID: 18528282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical diagnosis of renal neoplasms.
    Truong LD; Shen SS
    Arch Pathol Lab Med; 2011 Jan; 135(1):92-109. PubMed ID: 21204715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the Na+/K+-transporting ATPase gamma subunit FXYD2 in renal tumors.
    Gaut JP; Crimmins DL; Lockwood CM; McQuillan JJ; Ladenson JH
    Mod Pathol; 2013 May; 26(5):716-24. PubMed ID: 23196795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas.
    Huo L; Sugimura J; Tretiakova MS; Patton KT; Gupta R; Popov B; Laskin WB; Yeldandi A; Teh BT; Yang XJ
    Hum Pathol; 2005 Mar; 36(3):262-8. PubMed ID: 15791570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal cell carcinoma marker reliably discriminates central nervous system haemangioblastoma from brain metastases of renal cell carcinoma.
    Ingold B; Wild PJ; Nocito A; Amin MB; Storz M; Heppner FL; Moch H
    Histopathology; 2008 May; 52(6):674-81. PubMed ID: 18393979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of vitamin D3 receptor in kidney tumors.
    Liu W; Tretiakova M; Kong J; Turkyilmaz M; Li YC; Krausz T
    Hum Pathol; 2006 Oct; 37(10):1268-78. PubMed ID: 16949927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The utility of PAX-2 and renal cell carcinoma marker immunohistochemistry in distinguishing papillary renal cell carcinoma from nonrenal cell neoplasms with papillary features.
    Sharma SG; Gokden M; McKenney JK; Phan DC; Cox RM; Kelly T; Gokden N
    Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):494-8. PubMed ID: 21102195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Claudin-7 is highly expressed in chromophobe renal cell carcinoma and renal oncocytoma.
    Choi YD; Kim KS; Ryu S; Park Y; Cho NH; Rha SH; Jang JJ; Ro JY; Juhng SW; Choi C
    J Korean Med Sci; 2007 Apr; 22(2):305-10. PubMed ID: 17449941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study.
    Ordóñez NG
    Hum Pathol; 2004 Jun; 35(6):697-710. PubMed ID: 15188136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.